Sacubitril/valsartan - Novartis
Alternative Names: AHU-377/valsartan; dapagliflozin - Novartis; Enrest; Enresuto; Entresto; LCZ-696; LCZ-696A; Neparvis; Valsartan/AHU-377; Valsartan/sacubitrilLatest Information Update: 08 Feb 2024
At a glance
- Originator Novartis
- Developer Novartis; Rovi
- Class Antihypertensives; Biphenyl compounds; Branched-chain amino acids; Cardiovascular therapies; Erectile dysfunction therapies; Esters; Heart failure therapies; Pentanoic acids; Small molecules; Tetrazoles; Urologics
- Mechanism of Action Angiotensin type 1 receptor antagonists; Neprilysin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Essential hypertension; Heart failure; Hypertension
- Phase III Erectile dysfunction; Kidney disorders
- Phase II Hypertrophic cardiomyopathy
Most Recent Events
- 01 Feb 2024 Novartis plans a phase III trial for Hypertension (Treatment naïve, Monotherapy, Combination therapy) (PO, Tablet) (NCT06236061)
- 04 Dec 2023 Phase-III clinical trials in Heart failure (In children, In adolescents) in Japan (PO) (NCT06149104)
- 28 Nov 2023 Novartis Pharmaceuticals plans a phase III trial for Heart failure (In adolescents, In children) in December 2023 (PO, capsule) (NCT06149104 )